| 摘要 |
<p>Disclosed are novel pyrimido compounds of the formula (I) wherein R1 to R9 are as defined in the specification, that are selective inhibitors of both KDR an FGFR kinases and are selective against LCK. These compounds and their pharmaceutically acceptable salts are anti-proliferative agents useful in the treatment or control of solid tumors, in particular breast, colon, lung and prostate tumors. Also disclosed are pharmaceutical compositions containing these compounds and the use for 10 treating cancer.</p> |
